Beacon News

Why we need CO2, and How GreenChek Plans on Cashing in on it

The term “greenhouse effect” carries a negative connotation – but the gases involved actually serve as the earth’s thermostat. Carbon dioxide is just one of the necessary gases involved in the process, along with water vapor (H2O), methane, notorious oxide and a few others. The gases hold in heat like the glass walls of a greenhouse; without them, heat from the sun would escape our earth at night and the planet’s surface temperature would quickly fall below zero.

• Currently 3/5 Stars.
• 1
• 2
• 3
• 4
• 5

This Big Planet Needs Some Change, and CABN Plans to Deliver

Our lives and everyday activities revolve around transportation and fuel delivery infrastructure. As we, as a planet, grow more industrialized and more populous, our dependency on fossil fuels surpasses nearly every other need. Numerous alternative energies and carbon mitigation processes have been presented as “the way of the future,” promising cleaner air, a healthier planet and lower energy costs. So with all these options, why hasn’t one method acted as a bellwether for change? Because they all need substantial infrastructure changes.

• Currently 3/5 Stars.
• 1
• 2
• 3
• 4
• 5

Extended Tax Credit Heats up Solar Stocks, Brightens Prospects for U.S. as a Global Market Leader

Following numerous attempts to extend the tax incentives this year, which are set to expire at the end of the year, the Senate finally got to work on passing the Investment Tax Credit. The U.S. Senate voted Tuesday to extend solar tax credits for the next eight years and also remove the $2,000 cap on residential projects. According to observers, this approval has made final passage by the House and the President almost certain.

• Currently 3/5 Stars.
• 1
• 2
• 3
• 4
• 5

Bristo-Myers Squibb Determined on ImClone Systems Inc. (IMCL) Takeover, Sweetens Bid

Grabbing headlines in the pharmaceutical-biotech merger front, New York-based pharmaceuticals manufacturer Bristol-Myers announced it increased its offer for ImClone Systems Inc. to $62 a share in cash and will take the offer directly to shareholders of the New York oncology-drug specialist.

• Currently 3/5 Stars.
• 1
• 2
• 3
• 4
• 5